CTLA4 and melanoma: Upon ipilimumab (anti-CTLA-4 blocking antibody) treatment in melanoma patients, a significant decrease in NK cell, ILC1 and ILC2 frequencies has been observed, associated with reduced expression of the inhibitory receptor CD96 [160].